United Therapeutics Corporation $UTHR Shares Sold by Bank of America Corp DE

Key Points

• Bank of America reduced its United Therapeutics stake by 2.8% in the first quarter, selling 5,705 shares and retaining 199,426 shares valued at approximately $118.3 million. Institutional investors collectively own 94.08% of the company.
• United Therapeutics beat quarterly EPS expectations with $7.27 per share versus the $6.86 consensus, although revenue fell 1.9% year over year to $783.3 million and missed estimates.
• Analysts remain broadly positive, with 11 Buy ratings and two Holds producing a “Moderate Buy” consensus and an average price target of $646. However, insiders sold 482,833 shares worth about $265.6 million over the past 90 days.

Bank of America Corp DE lessened its stake in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 2.8% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 199,426 shares of the biotechnology company's stock after selling 5,705 shares during the quarter. Bank of America Corp DE owned 0.47% of United Therapeutics worth $118,256,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in UTHR. Torren Management LLC acquired a new position in shares of United Therapeutics in the fourth quarter worth $26,000. Activest Wealth Management boosted its stake in shares of United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company's stock valued at $29,000 after acquiring an additional 56 shares during the last quarter. WealthCollab LLC increased its position in United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock worth $30,000 after purchasing an additional 38 shares in the last quarter. Rakuten Securities Inc. increased its position in United Therapeutics by 76.7% during the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company's stock worth $30,000 after purchasing an additional 46 shares in the last quarter. Finally, Entrust Financial LLC acquired a new position in United Therapeutics in the 4th quarter valued at about $31,000. Institutional investors and hedge funds own 94.08% of the company's stock.

Insider Activity at United Therapeutics

In other United Therapeutics news, EVP Paul A. Mahon sold 8,300 shares of the business's stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $517.05, for a total value of $4,291,515.00. Following the transaction, the executive vice president owned 45,172 shares in the company, valued at $23,356,182.60. The trade was a 15.52% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Martine A. Rothblatt sold 9,500 shares of the company's stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $518.74, for a total transaction of $4,928,030.00. Following the completion of the transaction, the chief executive officer directly owned 324,443 shares of the company's stock, valued at approximately $168,301,561.82. The trade was a 2.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 482,833 shares of company stock worth $265,555,592. 8.60% of the stock is currently owned by company insiders.

United Therapeutics Trading Up 2.7%

Shares of United Therapeutics stock opened at $532.94 on Friday. The company has a fifty day moving average price of $539.78 and a 200 day moving average price of $534.19. United Therapeutics Corporation has a twelve month low of $292.34 and a twelve month high of $609.35. The stock has a market cap of $22.62 billion, a price-to-earnings ratio of 19.07, a price-to-earnings-growth ratio of 1.74 and a beta of 0.59.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, beating the consensus estimate of $6.86 by $0.41. The company had revenue of $783.30 million for the quarter, compared to analyst estimates of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The firm's revenue was down 1.9% compared to the same quarter last year. During the same period last year, the company posted $6.41 earnings per share. Analysts forecast that United Therapeutics Corporation will post 26.65 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. Raymond James Financial started coverage on shares of United Therapeutics in a research note on Friday, April 10th. They set an "outperform" rating and a $700.00 price target on the stock. Weiss Ratings lowered shares of United Therapeutics from a "buy (b)" rating to a "buy (b-)" rating in a research report on Friday, July 31st. Royal Bank Of Canada dropped their target price on United Therapeutics from $704.00 to $677.00 and set an "outperform" rating for the company in a research note on Thursday. TD Cowen reiterated a "buy" rating on shares of United Therapeutics in a research report on Thursday, May 21st. Finally, Bank of America decreased their price target on United Therapeutics from $620.00 to $613.00 and set a "neutral" rating on the stock in a research note on Friday, July 10th. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. Based on data from MarketBeat, United Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $646.00.

Trending Headlines about United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Quarterly EPS exceeded expectations. United Therapeutics reported second-quarter earnings of $7.27 per share, above the approximately $6.82–$6.86 consensus and up from $6.41 a year earlier. Strong profitability, including a net margin above 40%, provides a supportive fundamental backdrop. United Therapeutics Q2 Earnings Surpass Estimates
• Positive Sentiment: Ralinepag remains a major potential catalyst. Management highlighted the submission of regulatory applications for ralinepag, while the Phase 3 program and other pipeline developments could diversify growth beyond the company’s established pulmonary hypertension products. Analysts view these milestones as helping offset near-term competitive pressure on Tyvaso. EPS Strength and Ralinepag’s Phase 3 Milestone
• Positive Sentiment: Analysts remain constructive. H.C. Wainwright reiterated a Buy rating with a $660 target, while RBC maintained Outperform despite lowering its target from $704 to $677. The revised RBC target still implies substantial upside based on the quoted market price. Buy Rating Reiterated on United Therapeutics
• Neutral Sentiment: Revenue missed expectations. Second-quarter revenue declined roughly 2% year over year to $783.3 million, below the $804.65 million analyst estimate. The shortfall reflects near-term pressure despite the EPS beat and pipeline progress. United Therapeutics Reports Second-Quarter Results
• Negative Sentiment: Executives disclosed sizable stock sales. CEO Martine Rothblatt sold 9,500 shares for approximately $4.9 million, and EVP Paul Mahon sold 8,300 shares for about $4.3 million. Although these transactions may be scheduled or personal, they represent reductions in insider ownership and can weigh on sentiment.

About United Therapeutics

United Therapeutics Corporation NASDAQ: UTHR is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source